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Abstract: Retinal dystrophies (RD) are clinically and genetically heterogenous disorders showing
mutations in over 270 disease-associated genes. Several millions of people worldwide are affected
with different types of RD. Studying the relevance of disease-associated sequence alterations will
assist in understanding disorders and may lead to the development of therapeutic approaches. Here,
we established a whole exome sequencing (WES) pipeline to rapidly identify disease-associated
mutations in patients. Sanger sequencing was applied to identify deep-intronic variants and to verify
the co-segregation of WES results within families. We analyzed 26 unrelated patients with different
syndromic and non-syndromic clinical manifestations of RD. All patients underwent ophthalmic
examinations. We identified nine novel disease-associated sequence variants among 37 variants
identified in total. The sequence variants located to 17 different genes. Interestingly, two cases
presenting with Stargardt disease carried deep-intronic variants in ABCA4. We have classified
21 variants as pathogenic variants, 4 as benign/likely benign variants, and 12 as variants of uncertain
significance. This study highlights the importance of WES-based mutation analyses in RD patients
supporting clinical decisions, broadly based genetic diagnosis and support genetic counselling. It is
essential for any genetic therapy to expand the mutation spectrum, understand the genes’ function,
and correlate phenotypes with genotypes.
Keywords: retinal dystrophy; mutations; novel variant; whole exome sequencing; Sanger sequencing;
deep-intronic variants
1. Introduction
Inherited retinal dystrophies (RD) are characterized by progressive vision loss, often
caused by degeneration of photoreceptor or retinal pigment epithelial cells. RD shows
clinical variability and genetic heterogeneity. Approximately 1 in 2000 individuals world-
wide are affected with different subtypes of RD, including cone-rod dystrophy (CRD),
macular dystrophy (MD), retinitis pigmentosa (RP), Stargardt disease (STGD), and Usher
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Syndrome [1,2]. To date, more than 270 genes were identified to be associated with
syndromic and non-syndromic forms of RD (https://sph.uth.edu/retnet; accessed data
30 September 2020). RD may be inherited as an autosomal dominant (AD), autosomal
recessive (AR), X-linked (XL), or mitochondrial traits. Rare forms of RP have also been
reported before, such as X-linked dominant inheritance, digenic diallelic, and triallelic
mutations [3]. Different genes are associated with similar clinical phenotypes being obsta-
cles to targeted genetic analyses. RD genes have diverse functions in signaling pathways,
the vitamin A retinoid visual cycle, metabolism, and visual pathways [4]. In addition,
mutations in the same gene can also give rise to different phenotypes [1]. Consequently,
the success rates of any gene therapeutic approach depend on detailed analyses of genetic
variants in each RD case.
Successful clinical trials to treat RPE65 gene defects demonstrated the feasibility of
gene replacement approaches [5–8]. The treatment was approved by the FDA (Voretigen
Neparvovec, Luxturna®) and the EU [9,10]. Currently, genetic therapies are also being
developed for other retinal diseases, e.g., targeting common pathogenetic pathways such
as vascular endothelial growth factor-related pathways involved in exudative age-related
macular degeneration (AMD) and diabetic retinopathy. However, in retinal dystrophies,
identification and understanding of the disease-causing mutation is still challenging due to
enormous genetic heterogeneity and the high variability of the clinical phenotypes [11–13].
Clear genotype–phenotype correlations have rarely been reported.
Next generation sequencing (NGS) is one of the most promising techniques to enable
rapid identification of genetic variants in the majority of an individual’s genome. Its large
potential in genetic analyses has been demonstrated in different studies aiming to detect
disease-causing mutations in RD cases [11,12,14–16]. The number of reported disease-
associated DNA variants has increased dramatically compared to the times when, e.g.,
Sanger sequencing or array-based mutation screening technologies provided the only
sequencing platforms available. Nevertheless, Sanger sequencing is still the gold standard
technique to verify disease-associated variants within larger families, as well as to screen
for selected variants in genomic regions poorly covered by NGS.
Recently, several groups demonstrated the pathogenicity of the deep-intronic vari-
ants in ABCA4, mutations that have been associated with STGD [17–20]. Many of these
deep-intronic variants affected splicing and led to, e.g., pseudoexon inclusion or exon skip-
ping through the disruption of the splicing process [18]. Identifying and understanding
disease-associated ABCA4 alleles in non-coding regions and their correlation with clinical
symptoms will help to decipher genotype-phenotype relationship. This will further be
essential for the development of targeted therapeutic approaches to treat ABCA4-associated
diseases.
In this study, we analyzed patients with clinical diagnoses of RP, CRD, STGD, MD, or
Usher syndrome. We performed WES and, in selected cases, correlated the genetic results
with detailed clinical analyses. We identified 37 likely causative variants in 26 unrelated
patients suffering from different types of RD. We found nine novel sequence variants.
Selected deep-intronic variants were analyzed in STGD cases. The complexity of our dataset
confirmed the importance of detailed correlations between WES and clinical diagnoses.
2. Material and Methods
2.1. Patients and Family Members
In total, 26 index patients and 24 family members (affected and unaffected) were
recruited to this study. All participants provided written informed consent and were
informed in detail about the project and consequences of the study. The study adhered to
the tenets of the Declaration of Helsinki and was approved by the local ethics committee
(Hannover Medical School, Germany (2576-2015) and Faculty of Medicine and Health
Sciences at the Carl-von-Ossietzky University Oldenburg, Germany (2018-097)).
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2.2. Ophthalmological Investigations
Affected patients with a clinical diagnosis of either RP, MD, CRD, STGD, or Usher
syndrome were included in this study. The patients underwent detailed ophthalmological
examinations including fundus autofluorescence (FAF), optical coherence tomography
(OCT), and electroretinogram (ERG) (Table S1). Detailed clinical data of 10 patients and
1 further family member are shown in Table S1.
2.3. DNA Extraction
EDTA blood samples from index patients and family members were collected. DNA
extraction was performed using GentraPuregene Kit (QIAGEN GmbH, Hilden, Germany)
according to manufacturer’s instructions.
2.4. Whole Exome Sequencing (WES)
We analyzed 26 patients suffering from different types of RD, among which 23 cases
were analyzed by WES (15 research-based WES analyses and 8 gene diagnostic WES
analyses) and 3 cases were analyzed by gene panel diagnostics. We performed the WES
either as previously described [21] or by applying the Twist Human Core Exome Kit
(Twist Bioscience) for DNA library preparation. Each WES analysis was enriched for
exons and flanking intronic regions. WES was performed with the paired-end protocol on
either the Illumina NextSeq500 or the NovaSeq6000 platform (Illumina, Berlin, Germany).
Sequence reads were mapped and annotated to the human reference genome (hg19) using
Varfeed and Varvis (VARVIS Version 1.15, Limbus Medical Technologies GmbH, Rostock,
Germany).
2.5. WES Analysis Pipeline
Stepwise analysis of causative variants was performed according to standard proce-
dures established in our lab to evaluate high-throughput datasets of cases diagnosed with
various RD. An in-house gene panel containing 619 putative and known RD-associated
genes was used for bioinformatic analyses to identify possible disease-causing variants.
The first steps of the bioinformatic filtering aimed to identify previously described
pathogenic/likely pathogenic variants (Figure 1, Step 1). Identified disease-associated
variants were re-evaluated based on available genotype–phenotype data, inheritance
patterns, and publicly available allele frequencies in different populations/ethnicities
(Gnom AD/GnomTotal). We considered a case to be solved when pathogenic or likely
pathogenic variants were identified in this step of the analysis. In those cases where we
did not find a plausible variant during the first filtering steps, we applied the in-house
RD-associated gene panel including 619 candidates and disease-associated genes for further
analysis (Figure 1, Step 2). In order to bioinformatically enrich for pathogenic variants in the
RD panel, we applied the following filtering steps: (i) synonymous changes (not predicted
to change the amino acid sequence) were excluded to enrich for more likely pathogenic
variants. (ii) The gnomAD (GnomTotal) database (https://gnomad.broadinstitute.org,
accessed data 25 February 2021) was used to filter all variants with allele frequencies of
<0.001 (different populations and ethnicities) to select for rare variants identified in the
index patient. (iii) The Varvis-internal network database “AllexesFound” (comparing the
frequencies of variants detected among labs using VarVis) was set to exclude those variants
that were detected ≥100 times among the contributing laboratories. If these filtering steps
did not reveal plausible candidate variants, we applied the same settings to the complete
WES data set (Figure 1, Step 3). Additionally, the inheritance pattern within the family
was used to filter variants, e.g., excluding homozygous variants in cases with autosomal
dominantly inherited RD. Occasionally, filtering steps were adapted to detect additional
variants that were filtered out before. In these cases, we set the filters “GnomTotal” and
“AllexesFound” to higher values to also consider more frequent variants and/or set the
filter Reads-Index (Coverage of the sequenced region) to a minimum of 10 (Figure 1, Step 4).
Synonymous variants were only analyzed in rare occasions.
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Figure 1. Bioinformatic pipeline to identify disease-causing mutations from WES datasets. We have performed the WES
analyses in four steps with different filter settings using the Varvis platform that enabled step-by-step analyses of disease-
associated variants in genomic DNAs derived from peripheral blood of individual patient. The filter “Variant Impact:
high or moderate” excludes synonymous changes (not predicted to change the amino acid sequence) to enrich for more
likely pathogenic variants. The filter “AllexesFound:” shows the number of persons in the allexes database that carry the
variant. The filter “GnomTotal:” described the population allele frequency from merged exome and genome data sets of the
gnomAD database. The filter “Coverage:” shows numbers of sequencing reads in the target region. The filter “Reads-Index:”
describes the numbers of reads at the position of the variant.
2.6. Classification of Sequence Variants
We classified the identified sequence variants into 5 categories to determine their
pathogenicity according to ACMG (American College of Medical Genetics). We eval-
uated allele frequencies (GnomAD), in silico predictions, co-segregation analysis, and
published data (e.g., previously described sequence variants or descriptions on the func-
tion of gene/gene product or the consequences of mutation of the gene/gene product) [22].
We considered published evidence to conclude on the pathogenicity of each individual
variant as summarized below:
1. Pathogenic variant: A strong evidence of pathogenicity of the variant was found.
This included: (i) The variant was described in literature as a clearly disease-causing
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mutation. (ii) Novel mutation causes damaging effects on the RNA and protein level,
such as canonical splice mutation, nonsense mutation, frameshift mutation, insertion,
and deletion. (iii) Mutation was validated by functional studies and segregated within
the family.
2. Likely pathogenic variant: there is evidence of pathogenicity which included: (i)
splice variants were verified by in silico-predicted splice defects. (ii) The novel
variant showed low allele frequencies or was predicted as pathogenic using in silico
programs (e.g., SIFT, MutationTaster, PolyPhen-2, MutationAssessor). (iii) The variant
was confirmed by functional studies or segregation analysis.
3. Variant of unsure significance (VUS): There is limited evidence of pathogenicity. This
variant does not fulfill the criteria of either pathogenic or benign, or the evidence is
conflicting.
4. Likely benign variant: There is evidence against pathogenicity, e.g., allele frequency is
much higher than expected for the disease or in silico prediction showed conflicting
results.
5. Benign variant: There is strong evidence against pathogenicity. This variant is proba-
bly not a disease-causing mutation, because: (i) The allele frequency is higher than
expected (e.g., >1% in GnomAD) for rare genetic diseases. (ii) The variant was ob-
served in healthy populations with inheritance patterns comparable to the affected
patient. (iii) Functional studies suggested no damaging effects on RNA or protein
level.
2.7. Sanger Sequencing
Sanger sequencing was used to confirm the sequence changes detected in WES. Fur-
thermore, previously published ABCA4 deep-intronic variants and co-segregation analyses
in family members were performed by Sanger sequencing. ABCA4 deep-intronic vari-
ants were analyzed by Sanger sequencing using genomic DNA from those STGD patients
that showed either no or only heterozygous pathogenic/likely-pathogenic variants in
the coding region of the ABCA4 gene. Sanger sequencing was performed as previously
described [21]. Sanger sequencing data were analyzed with the SnapGene software (GSL
Biotech LLC, Chicago, IL, USA).
3. Results
3.1. Patients and Clinical Characterizations
All patients described herein underwent ophthalmological and clinical examinations
and were characterized as either RP, CRD, Usher syndrome, STGD, or MD. We analyzed
26 unrelated patients: 10 cases with RP, 5 cases with CD/CRD, 2 cases with Usher syn-
drome, 7 cases with STGD, and 2 cases with MD (Table 1). Detailed clinical data were
available from 10 independent patients (008, 017, 019, 020, 021, 022, 023, 024, 025, 026) and
one affected family member (025 II.3). Fundus and OCT images are available from seven
patients (005, 008, 010, 011, 014, 018, 020) in which novel variants were detected (Figure S2).
The clinical data are summarized in Table S1. Most of the patients were Caucasians orig-
inating from Germany or Europe (Table 1). In total, 24 additional family members of
10 index patients were analyzed for familial co-segregation of variants identified in the
index patient (Figure 3). Sixteen patients presented single cases where additional material
from family members were not available.
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Table 1. RD-associated variants detected in this study.


























































































































007 f German CD
RP1L1
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c.[133C>T];[=] p.Arg45Trp 0.00002028 AD, AR Pathogenic 1 [29]
008 m Caucasian CRD
RIMS1
NM_001168407.1
c.[1919C>A];[=] p.Ser640Tyr Not found _ VUS No Novel
009 f German RP
PDE6A
NM_000440.2
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c.[451C>T];[=] p.Leu151Phe Not found AD Pathogenic No [31]
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Table 1. Cont.
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D.D.: Differential diagnosis. RP: retinitis pigmentosa. STGD: Stargardt disease. MD: macula dystrophy. CRD: Cone-rod dystrophy. CD: cone dystrophy. Usher: Usher syndrome.
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3.2. Whole Exome Sequencing Analysis
The hg19 was used to map the WES sequence reads. High-throughput exome data
of 15 affected patients (001, 002, 003, 004, 005, 006, 007, 008, 009, 010, 016, 017, 018, 019,
020) were analyzed using a bioinformatic pipeline applying the Varvis platform (VARVIS
Version 1.15, Limbus Medical Technologies GmbH, Rostock, Germany). Additionally, eight
patients (013, 015, 021, 022, 023, 024, 025, 026) underwent genetic diagnostic WES analyses,
whereas three patients (011, 012, 014) were analyzed applying diagnostic panels. Sanger
sequencing analyses verified the results from high-throughput analyses (Figure S1).
We identified 37 disease associated variants in 17 different genes, among which 9 are
novel variants and 28 are previously published (Table 1). We have classified 21 variants as
pathogenic variants, 4 as benign/likely benign, and 12 as variants of uncertain significance
based on co-segregation analysis, type of mutation, previous publications, and bioinfor-
matic prediction tools (Table 1). Of the novel variants, two (one in C2orf71 and one in MAK)
were classified to be pathogenic, whereas six (in RIMS1, PDE6A, RP1, PRPF8, OFD1, or
ABCA4) were categorized as VUS (Table 1). One novel sequence alteration in PROM1 was
found to be benign (Table 1).
Disease-associated variants in ABCA4, USH2A, RP1L1, and PROM1 were identified
in two or more cases. NR2E3, C2orf71, RIMS1, PDE6A, RP1, MAK, GUCA1A, MYO7A,
SNRNP200, RPE65, PRPF8, CTNNA1, and OFD1 were found to carry sequence alterations
in one case only (Table 1 and Figure 2A). A total of 59% of the detected variants are
nonsynonymous substitution. The categories of nonsense mutations and indel mutations
together account for 22% of the identified variants. In addition, 11% of the sequence
alterations were predicted to interfere with splicing, likely leading to splice defect of the
pre-mRNA transcript. Of note, three deep-intronic variants (8%) were identified in the
ABCA4 gene in two independent STGD-affected patients (Table 1 and Figure 2B).
 
Figure 2. Statistical analysis of RD-associated variants detected in this study. (A) Disease-associated genes detected in this
study. In total, 17 different genes were detected in 26 RD-affected patients. Disease associated genes are color coded. (B)
Distribution of different types of sequence variants in known RD-associated genes. Among 37 sequenced variants, 59%
nonsynonymous substitution was found, followed by 14% small InDel variants, 11% Splice variants, 8% nonsense variants,
and 8% deep-intronic variants.
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3.3. Co-Segregation Analysis
Co-segregation analysis of sequence variants was performed in available family mem-
bers. These analyses were possible in 10 cases (001, 003, 004, 005, 007, 011, 014, 022, 024,
025) (Figure 3, Figure S1).
 
Figure 3. Pedigrees of all RD-affected patients for whom co-segregation analyses were performed. Black arrowheads
indicate the affected index patients in each family. Filled symbols represent affected family members. Co-segregation
analyses were performed in the underlined family members. The numbers on the left side of the pedigrees refer to Table 1
and Table S1. Question mark: phenotype information not available. M: mutation. Ref: reference sequence.
The sequence variant c.4714C>T in USH2A was verified in family 003 and 004 by
co-segregation analysis and found to be likely benign (Figure 3). Based on the genotype of
the affected and unaffected family members, we found the c.4714C>T variant was located
in a cis conformation with a pathogenic c.2299del variant (Figure 3). These observations
were in line with previous publications [25,38].
The PROM1 variant c.1069G>C was detected in the index patient with RP disease
(014) and was also identified in the unaffected mother 014 I.1, indicating that this variant
likely is a benign variant.
A heterozygous likely pathogenic SNRNP200 c.3260C>T sequence alteration was
found in patient 016. Interestingly, patient 016 was affected with RP as well as a duplex
kidney with hypertrophy. The SNRNP200 mutation previously was described to be associ-
ated with RP [34], but not with duplex kidney with hypertrophy. Importantly, the family
anamnesis of patient 016 showed six additional family members (mother, two sisters of
the mother, grandfather, granduncle, grandaunt; samples and pedigree not available) that
reported kidney hypertrophy. This suggested that the SNRNP200 c.3260C>T mutation may
not only be associated with RP but also with phenotypes including duplex kidney and
kidney hypertrophy. However, digenic condition cannot be excluded in this case.
Surprisingly, four ABCA4 variants (c.5882G>A, c.6006-5T>G, c.3113C>T, c.1622T>C)
were found in the index patient 022. Based on previous publications, three sequence
alterations (c.5882G>A, c.3113C>T, c.1622T>C) are likely pathogenic variants [35–37].
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Co-segregation analyses with the unaffected son 022 II.1, who carried c.5882G>A and
c.6006-5T>G, suggested that both alterations locate to the same allele.
3.4. ABCA4 Deep-Intronic Variants Found in STDG-Patients
The seven STGD-affected patients (019, 021, 022, 023, 024, 025, 026) described herein
were initially analyzed by WES analyses to search for disease-associated mutations in
exons and flanking genomic regions. In the patient 019, we found a CTNNA1 c.1310C>T
variant which we classified as a VUS. All other STGD patients were associated with ABCA4
sequence alterations.
Three of the seven STGD-affected patients (022, 025, 026) carried two or more ABCA4
mutations which likely explain the disease phenotype (Table 1). In families 022 and 025,
the co-segregation confirmed the disease association of the detected sequence variants.
However, co-segregation analysis was not possible in family 026. The mutations (ABCA4:
c.3113C>T, c.1662T>C) carried by 021 have been reported as complex allele [39]. Thus, it
cannot be excluded that the detected variants locate in cis on the same allele and that, e.g.,
the presence of an additional deep-intronic variants was overlooked.
We applied Sanger sequencing analyses to verify the presence of previously published
deep-intronic variants in all STGD-affected patients. We analyzed 17 previously published
deep-intronic ABCA4 variants including 16 variants in intron 30 and intron 36, and one
well-characterized variant (c.4253+43G>A) in intron 28 [18–20,40]. Interestingly, in patient
023 two deep-intronic variants (ABCA4: c.4539+1770C>A and ABCA4: c.5196+1015A>G)
were identified without any indication for an exonic sequence alteration after WES diag-
nostic analysis. To the best of our knowledge, the combination of the two deep-intronic
variants c.4539+1770C>A and c.5196+1015A>G has not been previously reported. Our
findings suggested a possible pathogenicity of the two deep-intronic ABCA4 variants
c.4539+1770C>A and c.5196+1015A>G. In contrast, 024 carried a single deep-intronic vari-
ant (ABCA4: c.4253+43G>A) together with the exonic frame-shifting mutation ABCA4:
c.6601_6602delAG. The c.4253+43G>A variant was previously characterized to lead to
splicing defects [19] and thus, was considered a likely pathogenic variant.
Of note, the ABCA4 deep-intronic variant c.4540-2169A>G was frequently found in
either a heterozygous (patient 019, 021, 022, 023, 026) or in a homozygous state (patient
025), suggesting a non-pathogenic nature of this sequence alteration. The allele frequency
of this variant was 0.56455 according to GnomAD (https://gnomad.broadinstitute.org/,
accessed data 25 February 2021).
Detailed clinic data of patients associated with STGD (including first diagnoses or
differential diagnoses of STGD) were available from seven independent patients (019, 021,
022, 023, 024, 025, 026) and one affected family member (025 II.3). The clinical data are
summarized in Table S1. The OCT images of the macular region of the two STGD-affected
patients 023 and 024, carrying deep-intronic variants are shown in Figure 4. Detailed
clinical characterization is presented in the following.
Patient 023: Patient 023 has been examined in the eye clinic since he was 50 years old.
Initial BCVA was OD (right eye) 20/20 and OS (left eye) 20/25 without indication of ambly-
opia. The patient suffered from metamorphopsia and increased photophobia. Color vision
impairment was negated, family history was unremarkable. Fundus examination showed
bilateral yellowish alterations of the retinal pigment epithelium (RPE) and circumscribed
areas of paracentral retinal atrophy. While spared in the left eye, atrophy partly covered
the fovea in the right eye. STGD could not be confirmed by standard genetic diagnostics at
the time. Furthermore, there was no genetic evidence for the differential diagnoses central
areolar choroidal dystrophy (CACD) and pattern dystrophy. In the course of the disease,
the patient reported gradual bilateral visual deterioration, reduced contrast perception and
a paracentral visual field impairment in the left eye. BCVA was reduced to 20/40 OU (both
eyes), perimetry showed deep central and paracentral scotomas. Retinal imaging revealed
progressive complete RPE and outer retinal atrophy (cRORA) and, consequently, regression
of the former spared “foveal islands” of cones in the left eye. Multifocal electroretinogram
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(mERG) detected reduced amplitudes in the central area in both eyes (described in Table S1).
Color vision testing results were unspecific. In spite of the rather mild clinical appearance,
STGD was still suspected.
Figure 4. Optical coherence tomography (OCT) images of the macular region of patient 023 and 024 carrying ABCA4
deep-intronic variants. Genetic nomenclature of the variants identified in ABCA4 is shown above the OCT images. OD:
oculus dexter, right eye. OS: oculus sinister, left eye.
Patient 024: Patient 024 has been presented at the eye clinic since he was 53 years old.
Initial best corrected visual acuity (BCVA) was OD 20/20 and OS 20/25 without indication
of amblyopia. The patient suffered from bilateral paracentral visual field impairment since
he was 50 years old. Color vision impairment and increased photophobia were negated,
the family history was unremarkable. Fundus examination showed bilateral bright spots
and yellowish lipofuscin deposits. Due to their pattern in the corresponding infrared image
and hyperautofluorescence, pattern dystrophy was suspected at first and genetic testing
was renounced. The differential diagnosis was STGD. Over time, the patient developed
progressive bilateral symptoms including metamorphopsia and visual field impairment.
BCVA was moderately reduced (OD 20/25, OS 20/32), perimetry showed partly deep para-
central scotomas. Retinal imaging (OCT, fundus autofluorescence) revealed progression by
detecting new, partly confluent lesions and spots of cRORA (Figure 4). Interestingly, foveal
sparing could be observed. Though clinical appearance was comparably mild, STGD was
suspected in the course of the disease.
4. Discussion
In the era of gene therapy, it is essential to develop efficient screening strategies to
identify and evaluate the pathogenicity of sequence alterations in patients with genetic
diseases. Here, we have shown that WES analysis can successfully be applied to cases
with RD. Compared to the classic Sanger sequencing, WES shows significant advantages
due to the enormous sequencing capacities. Because of the continuous improvement of
NGS techniques in recent years, the quality and the coverage of the sequencing reads
have increased tremendously [41]. In addition, WES technologies enable the simultaneous
analysis of many patient samples on the same sequencing platform. Although whole
genome sequencing has become the reality, WES is still the most reliable and cost-effective
method for routine application in identifying disease-associated sequence variants in
monogenetic diseases [42,43]. Since standard diagnostic testing often analyzes a subset of
disease-associated genes, the modern WES analysis is a powerful alternative to overcome
these drawbacks.
Nevertheless, Sanger sequencing still is the common procedure to verify sequence
changes detected by WES, to analyze short disease-associated genes (e.g., GJB2 and 6) or
to complement WES for difficult-to-enrich sequence regions. The genetic heterogeneity
associated with many diagnoses limits the applicability of Sanger sequencing approaches,
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as well as of other techniques, e.g., array-based mutation screenings, arrayed primer
extension (APEX) technology, or microarray-based sequencing approaches [44].
WES analyses in RD cases typically show a mutational detection rate of about 60 to
70% [12,13,45,46]. Thus, approximately one third of the cases cannot be solved by WES.
Possible explanations for this observation are, among others, that (i) insertions, deletions
or copy number variations are not reliably detected, (ii) synonymous mutations often
are difficult to interpret, (iii) deep intronic, promotor or intragenic mutations cannot be
detected, and (iv) non-genetic causes of the disease cannot be excluded [13,47]. Even
in cases where in silico analyses suggested the pathogenicity of a sequence alteration,
functional studies and/or co-segregation analyses might still be required to evaluate these
individual sequence changes [48].
We have established a WES pipeline applying a large gene panel that included known
as well as candidate genes associated with RD. In cases with an unambiguous clinical
phenotype, the analysis of previously published pathogenic genes and variants is the most
straightforward strategy. To minimize the possibility of overlooking potential candidate
variants, analysis of the whole exome was performed.
Here, we observed consanguinity in patient 006 based on the patient data collected by
clinicians, in which compound heterozygous variants (c.[3514C>A];[=], c.[130C>G];[=]) in
RP1L1 gene were identified. Interestingly, homozygous mutation c.5882G>A in ABCA4
gene was identified in patient 026, which strongly suggests consanguinity in the family.
However, the family anamnesis of the patient does not support this hypothesis. The
majority of the patients (001, 002, 004, 007–011, 013–017, 019–023) are nonconsanguineous
offspring in this study. In the remaining cases (003, 005, 012, 018, 024, 025), there are no
clear indications of consanguinity.
In two patients diagnosed with STGD, deep-intronic ABCA4 variants were identified.
Interestingly, one of the patients even showed two deep-intronic variants, while exonic
mutations were not detected. Obvious differences in the clinical presentation were not
observed between the two patients carrying deep-intronic variants in ABCA4. The pre-
viously described disease onset of patients carrying the c.4253+43G>A variant ranged
from 18 to 61 years, thus suggesting a variable age of onset or clinical severity associ-
ated with the variant c.4254+43G>A [18]. Patient 024 described herein (c.(4253+43G>A;
6601_6602delAG)) showed the first signs of STGD at an age of 50 years. In support, the
intronic variant c.4253+43G>A (p.Ile1377Hisfs*3) previously was characterized and was
shown to cause partial skipping of exon 28, which resulted in a frame shift and premature
stop codon in exon 28 of ABCA4 [18,40]. Our findings will help to correlate this intronic
mutation with the clinical severity. Since splicing represents a highly complex nuclear
process which is modulated by many, often weak, protein–protein or protein–RNA interac-
tions, it will be interesting to further analyze the correlation between clinical presentation
and haplotype-dependent efficacy of ABCA4 exon 28 splicing.
In addition to the c.4253+43G>A sequence alteration [18–20,40], the two deep intronic
variants c.4539+1770C>A and c.5196+1015A>G [19] might further help to explain the
missing heritability in STGD-affected patients lacking clear mutations in ABCA4 exons.
Although our data led to the hypothesis that these two variants are associated with STGD,
there is no experimental evidence supporting the pathogenicity of these two variants. In
our study, this possible genotype-phenotype correlation was observed for the first time.
Additional studies will be required to verify this notion.
In summary, WES is a reliable and cost-effective method to identify disease associated
variants, which may, in selected cases, require complementary sequencing techniques to
analyze deep-intronic variants. The WES pipeline described herein complements previous
publications, expands the RD mutation spectrum, and broadens the phenotype–genotype
correlation in the retinal diseases. A comprehensive clinical–genetical analysis of the
affected patients will be essential to support the recent attempts to develop gene therapeutic
approaches.
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